Related Experiment Video
Updated: Jul 12, 2026
07:40
Visualizing Lymph Node Structure and Cellular Localization using Ex-Vivo Confocal Microscopy
Published on: August 9, 2019
Iosimenol, a new non-ionic dimeric contrast medium, does not induce immunoreactivity in the popliteal lymph node
M J Fernandez Cabezudo1, G Petroianu, B Al-Ramadi
1Department of Biochemistry, Faculty of Medicine and Health Sciences, United Arab Emirates University, PO Box 17666, Tawam Street, Al Ain, Abu Dhabi, UAE.
The British Journal of Radiology
|September 5, 2007
Summary
The new contrast medium iosimenol showed no immunological effects in mouse studies. This finding suggests iosimenol may be a safe option for high-risk patients needing contrast imaging.
Area of Science:
- Immunology
- Radiology
- Pharmacology
Background:
- Non-ionic dimeric contrast media (CM) are essential in medical imaging.
- Assessing the immunogenicity of new CM is crucial for patient safety.
- Iosimenol is a novel non-ionic dimeric CM requiring safety evaluation.
Purpose of the Study:
- To evaluate the potential immunoreactivity of the new contrast medium iosimenol.
- To compare the immunological profile of iosimenol with iodixanol.
- To determine the safety of iosimenol for clinical use, particularly in high-risk populations.
Main Methods:
- Animal studies were conducted using mice.
- Potential immunoreactivity was assessed using passive lymph node assay (PLNA) and flow cytometry.
- Streptozotocin (STZ) and vehicle injections served as positive and negative controls, respectively.
Main Results:
- No significant immunological effects were observed with iosimenol.
- Comparative analysis with iodixanol did not reveal differential immunoreactivity.
- Control groups showed expected responses, validating the study's methodology.
Conclusions:
- The new contrast medium iosimenol demonstrates a lack of immunogenicity in preclinical studies.
- Iosimenol presents a potentially safer alternative for contrast-enhanced imaging procedures.
- Further clinical investigation is warranted to confirm the safety and efficacy of iosimenol in high-risk patient groups.
